Azenta, Inc. (NASDAQ:AZTA) Given Consensus Recommendation of “Hold” by Brokerages

Posted by on May 23rd, 2026

Shares of Azenta, Inc. (NASDAQ:AZTA – Get Free Report) have been given an average rating of “Hold” by the eight research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $39.50.

Several research firms recently weighed in on AZTA. Evercore reduced their target price on shares of Azenta from $50.00 to $45.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Wall Street Zen lowered shares of Azenta from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Jefferies Financial Group reduced their target price on shares of Azenta from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Wednesday, February 4th. Weiss Ratings upgraded shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Finally, Zacks Research upgraded shares of Azenta from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th.

Check Out Our Latest Research Report on AZTA

Hedge Funds Weigh In On Azenta

Hedge funds and other institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Azenta by 2,067.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock valued at $27,000 after acquiring an additional 765 shares in the last quarter. Assetmark Inc. lifted its holdings in shares of Azenta by 54.1% during the 4th quarter. Assetmark Inc. now owns 832 shares of the company’s stock valued at $28,000 after acquiring an additional 292 shares in the last quarter. Bessemer Group Inc. lifted its holdings in shares of Azenta by 249.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,017 shares of the company’s stock valued at $29,000 after acquiring an additional 726 shares in the last quarter. Osaic Holdings Inc. increased its stake in Azenta by 44.9% during the 2nd quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after buying an additional 385 shares during the period. Finally, Rockefeller Capital Management L.P. increased its stake in Azenta by 98.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock worth $46,000 after buying an additional 689 shares during the period. Institutional investors and hedge funds own 99.08% of the company’s stock.

Azenta Stock Up 3.3%

Shares of AZTA opened at $20.18 on Friday. The firm has a market cap of $930.10 million, a PE ratio of -5.10 and a beta of 1.43. The company’s fifty day moving average is $21.59 and its two-hundred day moving average is $29.03. Azenta has a fifty-two week low of $15.93 and a fifty-two week high of $41.73.

Azenta (NASDAQ:AZTA – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.16). The company had revenue of $144.80 million during the quarter, compared to analyst estimates of $148.47 million. Azenta had a negative net margin of 30.49% and a positive return on equity of 1.23%. The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.01 EPS.

Azenta Company Profile

(Get Free Report)

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.

Featured Articles

Analyst Recommendations for Azenta (NASDAQ:AZTA)

Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.